We propose to operate a state-of-the-art genome center to serve the scientific community. The Center will: (i) Have the flexible capability to produce a wide range of high-quality sequencing products - including whole-genome resequencing, whole-exome resequencing, de novo genome assembly, whole-transcriptome analysis, and epigenomic sequencing; (ii) Have the experience and ability to design, execute and analyze a wide range of scientific projects - including in medical genetics, cancer genomics, vertebrates genomics, microbial genomics and epigenomic analyses; (iii) Advance the state-of-the-art of sequencing - including by decreasing costs, developing new applications and pioneering new sequencing technologies;and (iv) Serve as a scientific resource for the biomedical community - including by creating and teaching courses, interacting with the research community to help with project design and working with the medical community to adapt protocols to clinical settings.

Public Health Relevance

The Center's program will accelerate biomedical research, including through systematic identification of genes responsible for inherited diseases, genes recurrently mutated in cancer, functional elements encoded in the human genome, and microbes that interact with humans in health and disease. The knowledge will be made rapidly and freely available to the scientific community. It will provide a foundation for efforts to develop understand disease mechanisms and to develop approaches to prevention, diagnosis and therapy.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54HG003067-10
Application #
8236205
Study Section
Special Emphasis Panel (ZHG1-HGR-P (O2))
Program Officer
Felsenfeld, Adam
Project Start
2003-11-10
Project End
2015-10-31
Budget Start
2011-11-01
Budget End
2012-10-31
Support Year
10
Fiscal Year
2012
Total Cost
$35,860,542
Indirect Cost
$3,123,447
Name
Broad Institute, Inc.
Department
Type
DUNS #
623544785
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Gao, Qingsong; Liang, Wen-Wei; Foltz, Steven M et al. (2018) Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep 23:227-238.e3
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Radovich, Milan; Pickering, Curtis R; Felau, Ina et al. (2018) The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 33:244-258.e10
Shen, Hui; Shih, Juliann; Hollern, Daniel P et al. (2018) Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep 23:3392-3406
Berger, Ashton C; Korkut, Anil; Kanchi, Rupa S et al. (2018) A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33:690-705.e9
Palkopoulou, Eleftheria; Lipson, Mark; Mallick, Swapan et al. (2018) A comprehensive genomic history of extinct and living elephants. Proc Natl Acad Sci U S A 115:E2566-E2574
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Grasso, Catherine S; Giannakis, Marios; Wells, Daniel K et al. (2018) Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov 8:730-749
Marin-Valencia, Isaac; Novarino, Gaia; Johansen, Anide et al. (2018) A homozygous founder mutation in TRAPPC6B associates with a neurodevelopmental disorder characterised by microcephaly, epilepsy and autistic features. J Med Genet 55:48-54
Schaub, Franz X; Dhankani, Varsha; Berger, Ashton C et al. (2018) Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst 6:282-300.e2

Showing the most recent 10 out of 349 publications